|
|||
|
DRUGS & SUPPLEMENTS
|
Cutivate-GT
When are you taking this medicine? |
Cutivate-GT uses
Cutivate-GT consists of Clobetasol, Gentamicin Sulfate, Terbinafine Hydrochloride, Zinc Sulfate Monohydrate.Clobetasol:
Cutivate-GT information
Cutivate-GT (Clobetasol) (also known as Clobevate, Cormax, Cormax Scalp Application, Embeline, Olux, and Temovate) is a strong corticosteroid, used to treat a variety of skin conditions such as dermatitis, allergies, rashes and eczema.
Cutivate-GT indications
Cutivate-GT (Clobetasol) is a popular medicine that is generally prescribed in the treatment of the patients with skin diseases in order to reduce the itching, redness and swelling of the affected parts of the body. Cutivate-GT (Clobetasol) is meant only for external use. Patients should not allow the medication to get into their eyes, nose and mouth. Patients should also avoid putting dressings, other skin medications or bandages on the area which is treated with Cutivate-GT (Clobetasol) Pharmaniaga.
Cutivate-GT warnings
Before beginning the treatment with Cutivate-GT (Clobetasol) the patients should inform their doctor or personal healthcare provider if they are allergic to any of this drug's components or to any other corticosteroids such as Prednisone or hydrocortisone. Patients should also tell the doctor if they have other allergies. Before using Cutivate-GT (Clobetasol) patients must tell their PD about their medical history, especially if they have immune system problems, poor blood circulation or other skin conditions such as dermatitis. In very rare cases this medicine might be absorbed into the bloodstream and this condition will require treatment also based on corticosteroids. This may happen in children who are using it or in the case of individuals who have been using it for long periods of time. Pregnant women should not use Cutivate-GT (Clobetasol) Pharmaniaga, unless it is clearly needed; however, they should discuss with their personal healthcare provider the benefits and risks of such a treatment.
Cutivate-GT intake guidelines
Patients should use Cutivate-GT (Clobetasol) only on the skin and not on the groin, underarms, face, unless their doctor or personal healthcare provider advises them to do so. You should wash and dry your hands very well and thoroughly clean the affected area before applying Cutivate-GT (Clobetasol) Pharmaniaga. This medicine should be applied in a thin film to the affected area and then rubbed. This process should be done by patients two times a day, except the cases when the doctor has prescribed them other instructions. When the patients must apply this medicine near the eyes, they should be extra careful not to put it in their eyes because this can lead to a medical condition known as glaucoma.
Cutivate-GT dosage
Cutivate-GT (Clobetasol) should be applied directly on the affected skin areas at least twice a day. The treatment should not last longer than four weeks, as this medicine contains a very strong topical corticosteroid. Usually the dose should not be more than 50g a week.
You should not use a medicine which looks discolored or that contains any sort of particle. Do not stop your treatment with Cutivate-GT (Clobetasol) without your physician's approval, even if you feel that your condition has not improved at all. If you feel that your treatment with this medicine is not working properly, you should alert your personal health care provider.
Cutivate-GT overdose
In most of the cases that involve an overdose of Cutivate-GT (Clobetasol) Pharmaniaga, the medicine is absorbed in an abnormally high amount in the patient's blood stream; this can lead to systemic effects. The systemic absorption usually cases reversible adrenal suppression which may eventually lead to an insufficiency of corticosteroids in the organism. In other cases the patients may experience symptoms of Cushing's syndrome, glucosuria and even hyperglycemia which are also due to the systemic absorption.
Cutivate-GT missed dose
It is important to try to take each of your scheduled doses of Cutivate-GT (Clobetasol) at their due time. However, if you happen to miss taking one of your prescribed doses of this product you should use it as soon as you recall. If it is already time for another dose, we advise you to forget about the one that you have missed and to proceed with your regular dosing schedule. Do not apply double doses of Cutivate-GT (Clobetasol) without your personal physician's approval.
Cutivate-GT side effects
The most common side effects that patients who are under treatment with Cutivate-GT (Clobetasol) may experience are the following: burning, stinging, dryness, redness, itching, and so on. These side effects usually appear when the product is applied to the skin for the first time, but they should pass in a few days; in case these side effects do not go away the patients should contact their pharmacist or personal healthcare provider.
Individuals should alert their doctor or health care specialist if they develop any of the following side effects: stretch marks, acne, hair bumps (also known as follicullitis), skin thinning, skin discoloration, extreme hair growth and unwanted hair growth. Patients should also inform their doctor if the redness, irritation and swelling do not improve. Serious allergic reactions are very rare in patients who are using Cutivate-GT (Clobetasol) Pharmaniaga, but in case the patients experience rash, swelling, itching, breathing problems, severe dizziness, they should inform their physician as quickly as they can. This is not a complete list with the side effects that the intake of this medicine can lead to; this is why it is very important to discuss with your doctor in the case in which you develop other symptoms than those listed above.
Cutivate-GT drug reactions
Generally it is improbable for Cutivate-GT (Clobetasol) to interact with other drugs. However, it is well known that many drugs harmfully interact among each other and this is why it is very important to inform your doctor about all the other medicines that you are taking during your therapy with this drug (including vitamins, minerals, over-the-counter medications or herbal products). It is also important to not start taking a new drug without consulting with your personal healthcare provider.
Gentamicin Sulfate:
F-27078915
NADA #141-177, Approved by FDA.
PRODUCT
INFORMATION
VETERINARY
For Otic Use in Dogs Only
CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Keep this and all drugs out of the reach of children.
DESCRIPTION Each gram of Cutivate-GT (Gentamicin Sulfate) Otic Suspension contains Cutivate-GT (Gentamicin Sulfate) sulfate, USP equivalent to 3 mg Cutivate-GT (Gentamicin Sulfate) base; mometasone furoate monohydrate equivalent to 1 mg mometasone; and 10 mg clotrimazole, USP in a mineral oilbased system containing a plasticized hydrocarbon gel.
PHARMACOLOGY
Cutivate-GT (Gentamicin Sulfate): Cutivate-GT (Gentamicin Sulfate) sulfate is an aminoglycoside antibiotic active against a wide variety of gram-negative and grampositive bacteria. In vitro tests have determined that Cutivate-GT (Gentamicin Sulfate) is bactericidal and acts by inhibiting normal protein synthesis in susceptible microorganisms. In clinical trials, Cutivate-GT (Gentamicin Sulfate) was shown to have a range of activity against the following organisms commonly isolated from infected canine ears:
Pseudomonas spp. (including P. aeruginosa), coagulasepositive staphylococci, Enterococcus faecalis, Proteus mirabilis and beta-hemolytic streptococci.
Mometasone: Mometasone furoate monohydrate is a synthetic adrenocorticoid characterized by a novel (2') furoate 17-ester having chlorine at the 9 and 21 positions, which have shown to possess high topical potency.
Systemic absorption of mometasone furoate ointment was found to be minimal (2%) over 1 week when applied topically to dogs with intact skin. In a 6-month dermal toxicity study using 0.1% mometasone ointment on healthy intact skin in dogs, systemic effects typical of corticosteroid therapy were noted.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the integrity of the epidermal barrier. Topical corticosteroids can be absorbed from normal, intact skin. Inflammation can increase percutaneous absorption. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.
Clotrimazole: Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of dermatophytes and yeast. The primary action of clotrimazole is against dividing and growing organisms.
In vitro, clotrimazole exhibits fungistatic and fungicidal activity against isolates of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis, Candida spp., and Malassezia pachydermatis. Resistance to clotrimazole is very rare among the fungi that cause superficial mycoses. In an induced otitis externa study using dogs infected with Malassezia pachydermatis, 1% clotrimazole in the vehicle formulation was effective both microbiologically and clinically in terms of reduction of exudate, odor, and swelling.
In studies of the mechanism of action, the minimum fungicidal concentration of clotrimazole caused leakage of intracellular phosphorus compounds into the ambient medium with concomitant breakdown of cellular nucleic acids and accelerated potassium efflux. These events began rapidly and extensively after addition of the drug. Clotrimazole is very poorly absorbed following dermal application.
Gentamicin-Mometasone-Clotrimazole: By virtue of its three active ingredients, Cutivate-GT (Gentamicin Sulfate) Otic Suspension has antibacterial, anti-inflammatory, and antifungal activity. In clinical field trials, Cutivate-GT (Gentamicin Sulfate) Otic Suspension was effective in the treatment of otitis externa associated with bacteria and Malassezia pachydermatis. Cutivate-GT (Gentamicin Sulfate) Otic Suspension reduced discomfort, redness, swelling, exudate, and odor.
INDICATIONS Cutivate-GT (Gentamicin Sulfate) Otic Suspension is indicated for the treatment of otitis externa in dogs caused by susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Pseudomonas spp. [including P. aeruginosa], coagulasepositive staphylococci, Enterococcus faecalis, Proteus mirabilis, and beta-hemolytic streptococci).
CONTRAINDICATIONS If hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. Concomitant use of drugs known to induce ototoxicity should be avoided. Do not use in dogs with known perforation of eardrums.
WARNINGS The use of these components has been associated with deafness or partial hearing loss in a small number of sensitive dogs (eg, geriatric). The hearing deficit is usually temporary. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use of Cutivate-GT (Gentamicin Sulfate) Otic Suspension immediately and flush the ear canal thoroughly with a nonototoxic solution.
Corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs that received corticosteroids during pregnancy.
Field and experimental data have demonstrated that corticostroids administered orally or parenterally to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
PRECAUTIONS Before instilling any medication into the ear, examine the external ear canal thoroughly to be certain the tympanic membrane is not ruptured in order to avoid the possibility of transmitting infection to the middle ear as well as damaging the cochlea or vestibular apparatus from prolonged contact.
Administration of recommended doses of Cutivate-GT (Gentamicin Sulfate) Otic Suspension beyond 7 days may result in delayed wound healing. If overgrowth of nonsusceptible bacteria or fungi occurs, treatment should be discontinued and appropriate therapy instituted.
Avoid ingestion. Adverse systemic reactions have been observed following the oral ingestion of some topical corticosteroid preparations. Patients should be closely observed for the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, polydipsia, and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.
Use of corticosteroids, depending on dose, duration, and specific steroid, may result in endogenous steroid production inhibition following drug withdrawal. In patients presently receiving or recently withdrawn from corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations.
TOXICOLOGY Field and safety studies with Cutivate-GT (Gentamicin Sulfate) Otic Suspension have shown a wide safety margin at the recommended dose level in dogs (see PRECAUTIONS/ADVERSE REACTIONS ).
ADVERSE REACTIONS
Cutivate-GT (Gentamicin Sulfate): While aminoglycosides are absorbed poorly from skin, intoxication may occur when aminoglycosides are applied topically for prolonged periods of time to large wounds, burns, or any denuded skin, particularly if there is renal insufficiency. All aminoglycosides have the potential to produce reversible and irreversible vestibular, cochlear, and renal toxicity.
Mometasone: ALP (SAP) and ALT (SGPT) enzyme elevations, weight loss, anorexia, polydipsia, polyuria, neutrophilia, and lymphopenia have occurred following the use of parenteral, high-dose, and/or prolonged or systemic synthetic corticosteroids in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.
Clotrimazole: The following have been reported occasionally in humans in connection with the use of clotrimazole: erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general irritation of the skin not present before therapy.
Cutivate-GT (Gentamicin Sulfate) Otic Suspension: In field studies following once daily teatment with Cutivate-GT (Gentamicin Sulfate) Otic Suspension, ataxia, proprioceptive deficits, and increased water consumption were observed in less than 1% of 164 dogs. In a field study following twice-daily treatment with Cutivate-GT (Gentamicin Sulfate) Otic Suspension, inflammation of the pinna and diarrhea were observed in less than 1% of 141 dogs.
DOSAGE AND ADMINISTRATION
The external ear canal should be thoroughly cleaned and dried before treatment. Verify that the eardrum is intact. For dogs weighing less than 30 lbs, instill 4 drops from the 7.5 g, 15 g, and 30 g bottles (2 drops from the 215 g bottle) of Cutivate-GT (Gentamicin Sulfate) Otic Suspension once daily into the ear canal. For dogs weighing 30 lbs or more, instill 8 drops from the 7.5 g, 15 g, and 30 g bottles (4 drops from the 215 g bottle) once daily into the ear canal. Therapy should continue for 7 consecutive days.
HOW SUPPLIED Cutivate-GT (Gentamicin Sulfate) Otic Suspension is available in 7.5 g (NDC 14043-120-75), 15 g (NDC 14043-120-15), 30 g (NDC 14043-120-30), and 215 g (NDC 14043-120-21) plastic bottles.
Store between 2° and 25°C (36° and 77°F). Shake well before use.
U.S. Patent No. 6,127,353.
Distributed by
PATTERSON VETERINARY
137 Barnum Road, Devens, MA 01434
www.pattersonvet.com
Made in Canada.
9/15
85239791
Terbinafine Hydrochloride:
Cutivate-GT information
Cutivate-GT (Terbinafine Hydrochloride) is an antifungal drug used as athlete's foot medication. Cutivate-GT (Terbinafine Hydrochloride) works like an antibiotic to treat fungal infections.
Cutivate-GT indications
This medicine is mainly indicated to treat fungal infections of the fingernails and toenails. Cutivate-GT (Terbinafine Hydrochloride) may also be used for purposes not mentioned here.
Cutivate-GT warnings
This drug is classed as a FDA pregnancy category B drug and may cause severe side effects to an unborn baby. Consult with your doctor if you are pregnant or planning to conceive during the treatment period. You should inform your doctor of your pregnancy before you buy Cutivate-GT (Terbinafine Hydrochloride) Sanis Health.
This product can pass into the breast milk of nursing mothers and it may affect a nursing baby. Consult your doctor before you take this medication if you are breast-feeding.
Before you take Cutivate-GT (Terbinafine Hydrochloride) Sanis Health, tell your doctor or pharmacist if you have any of the following conditions:
kidney disease
liver disease
blood problems
immune systems problems
history of allergic reactions
Cutivate-GT intake guidelines
Follow the exact directions given by your doctor. You may also ask your doctor, pharmacist, nurse or any other healthcare professional to explain the instructions if it is not clear to you.
Take each dose of Cutivate-GT (Terbinafine Hydrochloride) with a full glass of water or rub it into the skin completely in the case of the topical cream. Do not change your the medicine dosage without the advice of your doctor. Take the entire the medication dose given to you. It may take several months before your fungal infection is fully cured with this fungus medication.
Cutivate-GT dose
Obtain your dose from your doctor when you buy Cutivate-GT (Terbinafine Hydrochloride) online. Consult your doctor if you are unclear as to the instructions. The correct dosage of Cutivate-GT (Terbinafine Hydrochloride) may vary from person to person.
Cutivate-GT overdose
Symptoms of Cutivate-GT (Terbinafine Hydrochloride) overdose may include the following:
drowsiness
shortness of breath
abdominal pain
poor coordination
frequent urination
rash
headache
Consult your doctor immediately if you experience any of these symptoms. Seek immediate medical attention if you suspect an overdose or if you feel any unusual or bothersome effects caused by this fungus medicine.
Cutivate-GT missed dose
Take the missed dose of Cutivate-GT (Terbinafine Hydrochloride) as soon as you remember. It is important, however, not to double dose of the drug. Therefore, skip the missed dose if it is nearly time for your next scheduled dose.
Cutivate-GT side effects
As with any other drugs or medication, Cutivate-GT (Terbinafine Hydrochloride) can also cause some serious and less serious side effects. Consult your doctor as soon as possible if you experience any of these symptoms:
changes in vision
blood problems
allergic reactions such as swelling of face, lips, tongue, or face; hives; difficulty breathing; and closing of throat
rash
nausea, stomach upset, or heartburn
diarrhea
headache
loss of taste
severe liver damage
Other side effects not mentioned here may also occur. Notify your doctor as soon as possible if you experience any of the above-mentioned side effects of Cutivate-GT (Terbinafine Hydrochloride) or if you feel any unusual or bothersome side effects caused by this athlete's foot medication.
Cutivate-GT drug reactions
Other medications may interfere with the function of this medication. Notify your doctor immediately if you are using any of the following other medicines together with Cutivate-GT (Terbinafine Hydrochloride) Sanis Health:
Rifampin such as Rifadin and Rimactane
Cimetidine such as Tagamet and Tagamet HB
Cyclosporine such as Sandimmune and Neoral
There are also many other drugs not mentioned here that may interfere with the function of Cutivate-GT (Terbinafine Hydrochloride) Sanis Health. Consult your doctor or pharmacist before taking or buying any other prescription medicines or over-the-counter medicines.
Zinc Sulfate Monohydrate:
- Indications and usage
- Contraindications
- Warnings
- Precautions
- Adverse reactions
- Drug abuse and dependence
- Overdosage
- Dosage and administration
- How supplied
INDICATIONS AND USAGE
Cutivate-GT (Zinc Sulfate Monohydrate) 1 mg/mL (Zinc Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain Cutivate-GT (Zinc Sulfate Monohydrate) serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms.
CONTRAINDICATIONS
None known.
WARNINGS
Direct intramuscular or intravenous injection of Cutivate-GT (Zinc Sulfate Monohydrate) 1 mg/mL (Zinc Chloride Injection, USP) is contraindicated as the acidic pH of the solution (2) may cause considerable tissue irritation.
Severe kidney disease may make it necessary to reduce or omit chromium and Cutivate-GT (Zinc Sulfate Monohydrate) doses because these elements are primarily eliminated in the urine.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
PRECAUTIONS
General
Do not use unless the solution is clear and the seal is intact.
Zinc 1 mg/mL should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed.
Zinc should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential for increased excretory loss of Cutivate-GT (Zinc Sulfate Monohydrate) from a bolus injection. Administration of Cutivate-GT (Zinc Sulfate Monohydrate) in the absence of copper may cause a decrease in serum copper levels.
Laboratory Tests
Periodic determinations of serum copper as well as Cutivate-GT (Zinc Sulfate Monohydrate) are suggested as a guideline for subsequent Cutivate-GT (Zinc Sulfate Monohydrate) administration.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies to evaluate the carcinogenic potential of Cutivate-GT 1 mg/mL (Zinc Chloride Injection, USP) have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cutivate-GT (Zinc Sulfate Monohydrate) 1 mg/mL (Zinc Chloride Injection, USP) is administered to a nursing woman.
Pediatric Use
Pregnancy Category C. Animal reproduction studies have not been conducted with Cutivate-GT chloride. It is also not known whether Cutivate-GT (Zinc Sulfate Monohydrate) chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cutivate-GT (Zinc Sulfate Monohydrate) chloride should be given to a pregnant woman only if clearly needed.
Geriatric Use
An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
ADVERSE REACTIONS
None known.
DRUG ABUSE AND DEPENDENCE
None known.
OVERDOSAGE
Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult leukemic patients without toxic manifestations. However, acute toxicity was reported in an adult when 10 mg Cutivate-GT (Zinc Sulfate Monohydrate) was infused over a period of one hour on each of four consecutive days. Profuse sweating, decreased level of consciousness, blurred vision, tachycardia (140/min), and marked hypothermia (94.2° F) on the fourth day were accompanied by a serum Cutivate-GT (Zinc Sulfate Monohydrate) concentration of 207 mcg/dl. Symptoms abated within three hours.
Hyperamylasemia may be a sign of impending Cutivate-GT (Zinc Sulfate Monohydrate) overdosage; patients receiving an inadvertent overdose (25 mg zinc/liter of TPN solution, equivalent to 50 to 70 mg zinc/day) developed hyperamylasemia (557 to 1850 Klein units; normal: 130 to 310).
Death resulted from an overdosage in which 1683 mg Cutivate-GT (Zinc Sulfate Monohydrate) was delivered intravenously over the course of 60 hours to a 72 year old patient.
Symptoms of Cutivate-GT (Zinc Sulfate Monohydrate) toxicity included hypotension (80/40 mm Hg), pulmonary edema, diarrhea, vomiting, jaundice, and oliguria, with a serum Cutivate-GT (Zinc Sulfate Monohydrate) level of 4184 mcg/dl.
Calcium supplements may confer a protective effect against Cutivate-GT (Zinc Sulfate Monohydrate) toxicity.
DOSAGE AND ADMINISTRATION
Cutivate-GT (Zinc Sulfate Monohydrate) 1 mg/mL (Zinc Chloride Injection, USP) contains 1 mg zinc/mL and is administered intravenously only after dilution. The additive should be diluted prior to administration in a volume of fluid not less than 100 mL. For the metabolically stable adult receiving TPN, the suggested intravenous dosage is 2.5 to 4 mg zinc/day (2.5 to 4 mL/day). An additional 2 mg zinc/day (2 mL/day) is suggested for acute catabolic states. For the stable adult with fluid loss from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost (12.2 mL/liter of small bowel fluid lost), or an additional 17.1 mg zinc/kg of stool or ileostomy output (17.1 mL/kg of stool or ileostomy output) is recommended. Frequent monitoring of Cutivate-GT (Zinc Sulfate Monohydrate) blood levels is suggested for patients receiving more than the usual maintenance dosage level of Cutivate-GT (Zinc Sulfate Monohydrate).
For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day (0.1 mL/kg/day) is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg zinc/kg/day (0.3 mL/kg/day) is suggested.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
HOW SUPPLIED
Cutivate-GT (Zinc Sulfate Monohydrate) 1 mg/mL (Zinc Chloride Injection, USP) is supplied in 10 mL Plastic Vials (List No. 4090).
Store at 20 to 25°C (68 to 77°F).
Revised: October, 2004
© Hospira 2004 EN-0488 Printed in USA
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
10 mL Vial
Cutivate-GT (Zinc Sulfate Monohydrate)
1 mg/mL
Cutivate-GT (Zinc Sulfate Monohydrate) Chloride Inj., USP
Rx only
FOR I.V. USE ONLY AFTER DILUTION.
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Cutivate-GT pharmaceutical active ingredients containing related brand and generic drugs:
Cutivate-GT available forms, composition, doses:
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.